Fernandez, Hubert H
Robieson, Weining Z
Chatamra, Krai
Dubow, Jordan
Eaton, Susan
Benesh, Janet A
Odin, Per
Article History
Received: 18 December 2015
Revised: 19 February 2016
Accepted: 17 May 2016
First Online: 14 July 2016
Competing interests
: HHF was a study investigator and has received research support from Abbvie, Acadia, Biotie Therapeutics, EMD-Serono, Merck, Michael J Fox Foundation, Movement Disorders Society, NIH/NINDS, Novartis, Parkinson Study Group, Synosia, Teva, but has no owner interest in any pharmaceutical company; honoraria from Prime Education, Ohio State University, International Parkinson and Movement Disorders Society, Carling Communications, as a speaker in CME events; honoraria from Auspex Pharmaceuticals, Britannia, GE Health Care, Lundbeck, Merz Pharmaceuticals and Pfizer Pharmaceuticals, as a consultant; a stipend from International Parkinson and Movement Disorders Society for serving as Medical Editor of the MDS Web Site; royalties from Demos Publishing for serving as a book author/editor; and has contracts with Abbvie and Merz Pharmaceuticals for his role as a member of the Global Steering Committee for LCIG studies. HHF serves as the Head Principal Investigator for the Xeomin Registry Study, the Chair of the Publication Committee for Xeomin Studies (Merz Pharmaceuticals); and a member of the Publication Committee for Dysport studies (Ipsen Pharmaceuticals) but he does not receive any personal compensation for these roles. PO was a study investigator and has received compensation from AbbVie, Britannia, Ispen, Lundbeck, Nordic Infucare, and UCB for serving as consultant and/or lecturer, and has received honoraria from the Movement Disorder Society. WZR, KC, SE, and JAB are employees of AbbVie and hold stock and/or stock options. JD is a former employee of AbbVie receiving stock and/or stock options and is currently employed by Marathon Pharmaceuticals.